Top

Published in:

01-02-2015 | Original Article

Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer

Authors: Yong-il Kim, Hyung-Jun Im, Jin Chul Paeng, Gi Jeong Cheon, Keon Wook Kang, Dong Soo Lee, Do Joon Park, Young Joo Park, June-Key Chung

Published in: Annals of Nuclear Medicine | Issue 2/2015

Abstract

Objective

The utility of serum thyroglobulin (Tg) level, 3 days after radioactive iodine (RAI) therapy, was assessed as a means of predicting successful ablation of thyroid remnant in patients with postoperative thyroid cancer.

Methods

A total of 152 patients with thyroid cancer (mean age = 44.9 ± 13.7 year) undergoing RAI therapy after total thyroidectomy were included. Levels of TSH-stimulated Tg prior to ablation (stimTg) and serum Tg sampled immediately after RAI therapy (Day 3) were measured (immTg). ImmTg samples were collected during patient hospital visits for scheduled follow-up of radioiodine scans. Successful ablation was determined by the second time stimulated Tg levels (≤1 ng/ml) and negative radioiodine uptake at thyroid bed after 6.1 ± 1.1 months of RAI therapy. Univariate and multivariate analyses were done for immTg, stimTg, change in Tg levels (deltaTg: immTg − stimTg), immTg:stimTg ratio (ratioTg), and other potential clinical and pathologic markers of successful ablation.

Results

Of selected laboratory variables, ratioTg was a significant predictor of successful ablation. StimTg, tumor diameter, metastatic lymph node (LN) numbers, lymphatic invasion were possible clinical markers of successful ablation by univariate analysis. By multivariate analysis, ratioTg (odds ratio = 7.851), stimTg (odds ratio = 16.819), metastatic LN numbers (odds ratio with stimTg = 6.732) proved significant results. Furthermore, combining high ratioTg and low stimTg provided added predictive value.

Conclusions

High ratioTg (reflecting extensive release of Tg to the blood after RAI therapy) and low stimTg (reflecting small remnant thyroid tissue) constitute the indices of successful ablation after RAI therapy. Immediate Tg level could give an useful information on RAI ablation of postoperative thyroid remnant.

Verburg FA, Dietlein M, Lassmann M, Luster M, Reiners C. Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:343–6.CrossRefPubMed

Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol. 2005;153:651–9.CrossRefPubMed

Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.CrossRefPubMed

Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668–76.CrossRefPubMed

Verburg FA, de Keizer B, Lips CJ, Zelissen PM, de Klerk JM. Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur J Endocrinol. 2005;152:33–7.CrossRefPubMed

Karam M, Gianoukakis A, Feustel P, Cheema A, Postal E, Cooper J. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Nucl Med Commun. 2003;24:489–95.CrossRefPubMed

Paeng JC, Kang KW, Oh SW, Chung JK. Alternative medical treatment for radioiodine-refractory thyroid cancers. Nucl Med Mol Imaging. 2011;45:241–7.CrossRefPubMedCentralPubMed

Vaisman A, Orlov S, Yip J, Hu C, Lim T, Dowar M, et al. Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck. 2010;32:689–98.PubMed

Kendler DB, Vaisman F, Corbo R, Martins R, Vaisman M. Preablation stimulated thyroglobulin is a good predictor of successful ablation in patients with differentiated thyroid cancer. Clin Nucl Med. 2012;37:545–9.CrossRefPubMed

10.

Sawka AM, Orlov S, Gelberg J, Stork B, Dowar M, Shaytzag M, et al. Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma. Head Neck. 2008;30:693–700.CrossRefPubMed

11.

Park EK, Chung JK, Lim IH, Lee DS, Lee MC, Cho BY. Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. Eur J Nucl Med Mol Imaging. 2009;36:172–9.CrossRefPubMed

12.

Verkooijen RB, Rietbergen D, Smit JW, Romijn JA, Stokkel MP. A new functional parameter measured at the time of ablation that can be used to predict differentiated thyroid cancer recurrence during follow-up. Eur J Endocrinol. 2007;156:41–7.CrossRefPubMed

13.

Tamilia M, Al-Kahtani N, Rochon L, Hier MP, Payne RJ, Holcroft CA, et al. Serum thyroglobulin predicts thyroid remnant ablation failure with 30 mCi iodine-131 treatment in patients with papillary thyroid carcinoma. Nucl Med Commun. 2011;32:212–20.CrossRefPubMed

14.

Bernier MO, Morel O, Rodien P, Muratet JP, Giraud P, Rohmer V, et al. Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2005;32:1418–21.CrossRefPubMed

15.

Vrndic OB, Savin SB, Mijatovic LC, Djukic AA, Jeftic ID, Simonovic STZ. Concentration of thyroglobulin and thyroglobulin-specific autoantibodies in patients with differentiated thyroid cancer after treatment with radioactive iodine 131. Lab Med. 2011;42:27–31.CrossRef

16.

Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433–41.CrossRefPubMed

17.

Eustatia-Rutten CF, Smit JW, Romijn JA, van der Kleij-Corssmit EP, Pereira AM, Stokkel MP, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf). 2004;61:61–74.CrossRefPubMed

18.

Pelttari H, Valimaki MJ, Loyttyniemi E, Schalin-Jantti C. Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study. Eur J Endocrinol. 2010;163:757–63.CrossRefPubMed

19.

Toubeau M, Touzery C, Arveux P, Chaplain G, Vaillant G, Berriolo A, et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med. 2004;45:988–94.PubMed

20.

Webb RC, Howard RS, Stojadinovic A, Gaitonde DY, Wallace MK, Ahmed J, et al. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab. 2012;97:2754–63.CrossRefPubMed

21.

Lin JD, Huang MJ, Hsu BR, Chao TC, Hsueh C, Liu FH, et al. Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas. J Surg Oncol. 2002;80:45–51.CrossRefPubMed

22.

Gibelli B, Tredici P, De Cicco C, Bodei L, Sandri MT, Renne G, et al. Preoperative determination of serum thyroglobulin to identify patients with differentiated thyroid cancer who may present recurrence without increased thyroglobulin. Acta otorhinolaryngol Ital. 2005;25:94–9.PubMedCentralPubMed

23.

Ramakrishnan N, McClain DE, Catravas GN. Membranes as sensitive targets in thymocyte apoptosis. Int J Radiat Biol. 1993;63:693–701.CrossRefPubMed

24.

Nishiyama K, Kozuka T, Higashihara T, Miyauchi K, Okagawa K. Acute radiation thyroiditis. Int J Radiat Oncol Biol Phys. 1996;36:1221–4.CrossRefPubMed

Title: Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer
Authors: Yong-il Kim
Hyung-Jun Im
Jin Chul Paeng
Gi Jeong Cheon
Keon Wook Kang
Dong Soo Lee
Do Joon Park
Young Joo Park
June-Key Chung
Publication date: 01-02-2015
Publisher: Springer Japan
Published in: Annals of Nuclear Medicine / Issue 2/2015
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-014-0927-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer

Abstract

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2015

Axillary lymph node staging in breast cancer: clinical value of single photon emission computed tomography-computed tomography (SPECT-CT) with 99mTc-methoxyisobutylisonitrile

Diagnostic performance of bone scintigraphy analyzed by three artificial neural network systems

Clinical significance of diffuse hepatic uptake on post-therapeutic early and delayed 131I scan in differentiated thyroid cancer: a preliminary report

Assessment of human effective absorbed dose of 67 Ga–ECC based on biodistribution rat data

Acknowledgements to Reviewers

The potential usefulness of 18F-FDG PET/CT for detecting colorectal carcinoma and adenoma in asymptomatic adults